CD8A and myocarditis: Seven days after CVB3 infection (3LD50/mouse), the protection efficacy of myocarditis was significantly declined in mice group with CD8 mAb treatment verified by reduced LVEF and LVFS (Figures 5A,B), increased myocardial injury (Figure 5C), myocardial pathology (Figures 5D,E), and virus load (Figure 5F).